IVD 감염병 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The IVD Infectious Diseases Market size is expected to reach USD 23.43 Billion in 2034 from USD 17.63 Billion (2025) growing at a CAGR of 3.21% during 2026-2034.

The global IVD infectious diseases market is experiencing strong growth due to the increasing prevalence of infectious diseases worldwide. In vitro diagnostic (IVD) tests play a crucial role in detecting infections such as HIV, hepatitis, influenza, tuberculosis, and emerging viral diseases. Rapid and accurate diagnostic testing is essential for effective disease management and prevention of outbreaks.

Technological advancements in diagnostic platforms are significantly transforming the IVD market. Molecular diagnostics, polymerase chain reaction (PCR) tests, and rapid antigen testing methods are improving the speed and accuracy of infectious disease detection. The growing demand for point-of-care testing and portable diagnostic devices is also contributing to market expansion.

Looking ahead, the IVD infectious diseases market is expected to grow as global healthcare systems emphasize early disease detection and outbreak preparedness. Increasing investments in diagnostic research and the development of innovative testing technologies will support market growth. Rising awareness about preventive healthcare will further drive demand for infectious disease diagnostics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Instruments
• Reagents
• Software

By Technology

• Immunoassay
• Molecular diagnostics
• Microbiology
• Others

By Application

• MRSA
• Streptococcus
• Clostridium difficile
• VRE
• CRE
• Respiratory Virus
• Candida
• TB and drug-resistant TB
• Gastro-intestinal panel testing
• Chlamydia
• Gonorrhea
• HPV
• HIV
• Hepatitis C
• Hepatitis B
• COVID-19
• Other Infectious Diseases

By Test Location

• Point of Care
• Central Laboratories
• Others

COMPANIES PROFILED

• Qiagen, BD, bioMrieux SA, F HoffmannLa Roche Ltd, Hologic Inc Gen Probe, Abbott, Quidel Corporation, Siemens Healthineers AG, BioRad Laboratories Inc, Danaher, OraSure Technologies Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IVD INFECTIOUS DISEASES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IVD INFECTIOUS DISEASES MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Molecular diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Microbiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IVD INFECTIOUS DISEASES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. MRSA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Streptococcus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clostridium difficile Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. VRE Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. CRE Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Respiratory Virus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Candida Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. TB and drug-resistant TB Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Gastro-intestinal panel testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Chlamydia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Gonorrhea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. HPV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.14. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.15. Hepatitis C Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.16. Hepatitis B Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.17. COVID-19 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.18. Other Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IVD INFECTIOUS DISEASES MARKET: BY TEST LOCATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Test Location
• 7.2. Point of Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Central Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL IVD INFECTIOUS DISEASES MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Technology
  • 8.2.3 By Application
  • 8.2.4 By Test Location
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Technology
  • 8.3.3 By Application
  • 8.3.4 By Test Location
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Technology
  • 8.4.3 By Application
  • 8.4.4 By Test Location
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Technology
  • 8.5.3 By Application
  • 8.5.4 By Test Location
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Technology
  • 8.6.3 By Application
  • 8.6.4 By Test Location
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL IVD INFECTIOUS DISEASES INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Qiagen
  • 10.2.2 BD
  • 10.2.3 BioMAfA(C)Rieux SA
  • 10.2.4 F. Hoffmann-La Roche Ltd
  • 10.2.5 Hologic Inc. (Gen Probe)
  • 10.2.6 Abbott
  • 10.2.7 Quidel Corporation
  • 10.2.8 Siemens Healthineers AG
  • 10.2.9 Bio-Rad Laboratories Inc
  • 10.2.10 Danaher
  • 10.2.11 OraSure Technologies Inc